ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL

被引:17
作者
Shteper, PJ
Siegfried, Z
Asimakopoulos, FA
Palumbo, GA
Rachmilewitz, EA
Ben-Neriah, Y
Ben-Yehuda, D
机构
[1] Hadassah Univ Hosp, Dept Hematol, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91010 Jerusalem, Israel
[3] Univ Catania, Dept Hematol, Catania, Italy
基金
以色列科学基金会;
关键词
acute lymphoblastic leukemia; chronic myeloid leukemia; Philadelphia chromosome; ABL; methylation;
D O I
10.1038/sj.leu.2402026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In human Ph-positive leukemia there is a clear association of different forms of the BCR-ABL oncogene with distinct types of leukemia. The P190 form of BCR-ABL is rarely observed in chronic myeloid leukemia (CML) but is present in 50% of Ph-positive acute lymphoblastic leukemia (ALL). In contrast, the P210 form is observed both in CML and 50% of Ph-positive ALL. Methylation of the proximal promoter of the ABL1 gene has been shown to he a nearly universal event associated with clinical progression of CML. This raises the question of whether methylation of the ABL1 promoter is an epigenetic modification also associated with Ph-positive ALL. To study this issue, we used methylation-specific PCR and bisulfite sequencing to determine the methylation status of the ABL1 promoter in 18 Ph-positive ALL samples. We report here that gene-specific ABL1 promoter methylation is associated mainly with the P210 form of BCR-ABL and not the P190 form. While six out of the seven P210-positive ALL samples had ABL1 promoter methylation, none of the 11 P190-positive ALL samples demonstrated ABL1 promoter methylation. In addition, we estimated the extent and relative abundance of ABL1 promoter methylation in several Ph-positive ALL samples and compared it to the methylation pattern in chronic, accelerated and blastic crisis phases of CML. We put forth a model that correlates the different types of leukemias with the different levels of ABL1 promoter methylation.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 50 条
  • [41] A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph plus ALL
    Rix, Uwe
    Colinge, Jacques
    Blatt, Katharina
    Gridling, Manuela
    Rix, Lily L. Remsing
    Parapatics, Katja
    Cerny-Reiterer, Sabine
    Burkard, Thomas R.
    Jaeger, Ulrich
    Melo, Junia V.
    Bennett, Keiryn L.
    Valent, Peter
    Superti-Furga, Giulio
    [J]. PLOS ONE, 2013, 8 (10):
  • [42] Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress
    Leclerc, Guy J.
    DeSalvo, Joanna
    Du, Jianfeng
    Gao, Ningguo
    Leclerc, Gilles M.
    Lehrman, Mark A.
    Lampidis, Theodore J.
    Barredo, Julio C.
    [J]. LEUKEMIA RESEARCH, 2015, 39 (11) : 1246 - 1254
  • [43] Undifferentiated immunophenotypes and not expression of BCR-ABL can be associated in adult Mestizo Mexican patients with ALL
    Erasmo Vazquez-Franco, Jose
    Reyes-Maldonado, Elba
    Arcelia Montiel-Cervantes, Laura
    Angelica Lezama, Ruth
    [J]. REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (01): : 32 - 39
  • [44] Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone
    Winter, SS
    Greene, JM
    McConnell, TS
    Willman, CL
    [J]. LEUKEMIA, 1999, 13 (12) : 2007 - 2011
  • [45] p210BCR-ABL1- Chronic myeloid leukemia presents with monocytosis
    Wang, Xiaofei
    Wang, Fei
    Wang, Zie
    Li, Yuantang
    Wang, Devin
    Wu, Huanling
    Zhang, Bingchang
    [J]. CLINICAL CASE REPORTS, 2020, 8 (05): : 840 - 842
  • [46] Acute Lymphoblastic Leukemia Expressing b3a2 (p210), e1a2 (p190), and Variant e1a2 BCR-ABL Transcripts: A Case Report and Review of the Literature
    Tan, Yanhong
    Chen, Xiuhua
    Qi, Xiling
    Li, Guoxia
    Wang, Jingjing
    Bian, Sicheng
    Xu, Zhifang
    Wang, Hongwei
    [J]. ACTA HAEMATOLOGICA, 2012, 128 (02) : 119 - 123
  • [47] Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment
    Yeung, D. T.
    Moulton, D. J.
    Heatley, S. L.
    Nievergall, E.
    Dang, P.
    Braley, J.
    Branford, S.
    Moore, S.
    Mullighan, C. G.
    Hughes, T. P.
    White, D. L.
    [J]. LEUKEMIA, 2015, 29 (01) : 230 - 232
  • [48] p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia
    Mian, Afsar A.
    Metodieva, Anna
    Najajreh, Yousef
    Ottmann, Oliver G.
    Mahajna, Jamal
    Ruthardt, Martin
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02): : 251 - 257
  • [49] Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era
    Shi, Ting
    Xie, Mixue
    Chen, Li
    Yuan, Wei
    Wang, Yungui
    Huang, Xin
    Xie, Wanzhuo
    Meng, Haitao
    Lou, Yinjun
    Yu, Wenjuan
    Tong, Hongyan
    Ye, Xiujin
    Huang, Jinyan
    Jin, Jie
    Zhu, Honghu
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [50] The role of miRNA -181C between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
    Radhi, Kawthar Ali
    Hamzah, Israa Hussein
    Matti, Bassam Francis
    [J]. HUMAN GENE, 2022, 34